A Microbicide is any substance or process that kills germs (bacteria, viruses, and other microorganisms that can cause infection and disease). Also called germicide.
Women who took part in ASPIRE, a trial that found a vaginal ring containing an antiretroviral (ARV) drug called dapivirine was safe and helped protect against HIV, will soon be offered the opportunity to use the ring as part of a new study called HOPE.
In an important scientific achievement for women's health, two large Phase III clinical trials -- The Ring Study and ASPIRE -- have shown that a monthly vaginal ring containing the antiretroviral drug (ARV) dapivirine can safely help prevent HIV-1 infection in women.
Enemas are commonly used by men who have sex with men (MSM) and transwomen (TW) before sexual intercourse. But these groups are vulnerable to HIV and a host of other sexually transmitted infections because enemas -- even those that use tap water -- can seriously damage the thin tissue lining the rectum, allowing for easier transmission of harmful viruses and bacteria.
CONRAD is pleased to announce a new funding agreement, in collaboration with the U.S. President's Emergency Plan for AIDS Relief and the U.S. Agency for International Development, in support of a human centered design (HCD) strategy to increase demand, use and adherence of HIV prevention products for high risk women in Africa.
An unprecedented potential "molecular tweezer" called CLR01, reported in the journal eLife, not only blocks HIV and other sexually transmitted viruses, but also breaks up proteins in semen that boost infection.
In a first for HIV prevention, an international team of researchers have completed follow-up of participants enrolled in a pivotal Phase III trial that tested the safety and effectiveness of a vaginal ring for preventing HIV in women.
Dr. Deborah Anderson from Boston University School of Medicine (BUSM) and her colleagues are challenging dogma about the transmission of the human immunodeficiency virus type 1 (HIV-1).
The Population Council will present new research on novel approaches to HIV, sexually transmitted infections (STIs), and unintended pregnancy prevention at the HIV Research for Prevention Conference, (HIV R4P) in Cape Town, South Africa. HIV R4P, which runs 28–31 October, is the first global scientific meeting dedicated exclusively to research on biomedical HIV prevention.
The Miriam Hospital is part of a research collaboration that has received a $20 million grant from the National Institutes of Health (NIH) to develop an intravaginal ring (IVR) that can deliver powerful antiretroviral (ARV) drugs to prevent the spread of sexually transmitted HIV in women.
A unique method for delivering compounds that could positively impact the global battle against HIV and AIDS may be possible, thanks to researchers in Penn State's College of Agricultural Sciences.
Scientists at the University of Nebraska-Lincoln College of Engineering's Biological Process Development Facility have successfully produced a drug compound with potential to block HIV transmission in women.
ASPIRE, one of two Phase III trials of a promising method for preventing HIV in women - a vaginal ring worn for a month at a time - has completed enrollment of participants, with 2,629 women from 15 clinical research sites in Malawi, South Africa, Uganda and Zimbabwe now taking part in the study.
The International Partnership for Microbicides announced today that it has received exclusive worldwide rights to a promising HIV prevention medicine called dapivirine from Janssen R&D Ireland, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Janssen R&D Ireland Ltd. (Janssen) today announced that it has expanded its collaboration with the International Partnership for Microbicides (IPM) for the development and delivery of dapivirine (TMC120) for the prevention of HIV.
Population Council scientists and their partners have found that their proprietary microbicide gel is safe, stable, and can prevent the transmission of multiple sexually transmitted infections (STIs) in both the vagina and rectum in animals: HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV).
Findings of an early phase clinical trial at the University of Alabama at Birmingham suggest that a possible new method of protecting women from the transmission of HIV is safe.
Two early clinical studies of novel HIV prevention products for women - the first combination antiretroviral (ARV) vaginal ring and a vaginal film - show the products to be safe and open the door to product improvements that could expand options for women-initiated prevention tools. The results of both studies were presented today at the 21st Conference on Retroviruses and Opportunistic Infections.
Women who used an injectable contraceptive called DMPA were more likely to acquire HIV than women using a similar product called NET-EN, according to a secondary analysis of data from a large HIV prevention trial called VOICE, researchers from the National Institutes of Health-funded Microbicide Trials Network reported today at the 21st Conference on Retroviruses and Opportunistic Infections in Boston.
The University of North Carolina at Chapel Hill has received a seven-year, more than $40 million award from the National Institutes of Health for a clinical trials unit that will implement the scientific agendas of five NIH networks devoted to HIV/AIDS treatment, prevention, and cure research.
CONRAD, a leading reproductive health-research organization based at Eastern Virginia Medical School (EVMS), today announced that they are a winner of the United States Agency for International Development (USAID) Science and Technology Pioneers Prize for their work in developing tenofovir gel.